prikaz prve stranice dokumenta Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP
  Preuzmi
PDF 247.77 KB
Znanstveni rad - Izvorni znanstveni rad
Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP
Pathology Oncology Research, 17 (2011), 2; 243-247. https://doi.org/10.1007/s12253-010-9304-4
Mitrović, Zdravko; Ilić, Ivana; Aurer, Igor; Bašić-Kinda, Sandra; Radman, Ivo; Dotlić, Snježana; Ajduković, Radmila; Labar, Boris

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Mitrović, Z., Ilić, I., Aurer, I., Bašić Kinda, S., Radman, I., Dotlić, S. ... Labar, B. (2011). Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP. Pathology Oncology Research, 17. (2), 243-247. doi: 10.1007/s12253-010-9304-4

Mitrović, Zdravko, et al. "Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP." Pathology Oncology Research, vol. 17, br. 2, 2011, str. 243-247. https://doi.org/10.1007/s12253-010-9304-4

Mitrović, Zdravko, Ivana Ilić, Igor Aurer, Sandra Bašić Kinda, Ivo Radman, Snježana Dotlić, Radmila Ajduković i Boris Labar. "Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP." Pathology Oncology Research 17, br. 2 (2011): 243-247. https://doi.org/10.1007/s12253-010-9304-4

Mitrović, Z., et al. (2011) 'Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP', Pathology Oncology Research, 17(2), str. 243-247. doi: 10.1007/s12253-010-9304-4

Mitrović Z, Ilić I, Aurer I, Bašić Kinda S, Radman I, Dotlić S, i sur.. Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP. Pathology Oncology Research [Internet]. 06.2011. [pristupljeno 25.12.2024.];17(2):243-247. doi: 10.1007/s12253-010-9304-4

Z. Mitrović, et al., "Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP", Pathology Oncology Research, vol. 17, br. 2, str. 243-247, Lipanj 2011. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:221136. [Citirano: 25.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:221136
Podaci o radu
Naslov (engleski)Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP
AutorZdravko Mitrović
AutorIvana Ilić
AutorIgor Aurer
AutorSandra Bašić-Kinda
AutorIvo Radman
AutorSnježana Dotlić
AutorRadmila Ajduković
AutorBoris Labar
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Survivin is an inhibitor of apoptosis whose expression may be associated with inferior outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated without rituximab. Caspase-3 is the final caspase of the apoptotic cascade and its pattern of expression may also be related to patients' outcome. In this study we investigated immunohistochemical expression of survivin and caspase-3 (CPP32) in 57 patients with DLBCL treated with rituximab and CHOP (R-CHOP). According to previously published criteria, we separately analyzed correlation of different types of survivin expression with patients' outcome. Nuclear survivin was expressed in only 26% of cases, cytoplasmic survivin was expressed in 81% of cases while application of immunoreactivity scoring system yielded 58% of survivin positive cases. Caspase-3 was expressed in 77% of cases. There were no significant correlations between any type of survivin expression and response to treatment or survival of the patients. The expression of caspase-3 was also not associated with patients' outcome. We conclude that survivin and caspase-3 have no significant prognostic significance in patients with DLBCL treated with R-CHOP.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaPathology Oncology Research
Brojčani podacivol. 17, br. 2, str. 243-247
p-ISSN1219-4956
DOIhttps://doi.org/10.1007/s12253-010-9304-4
URN:NBNurn:nbn:hr:105:221136
Datum objave publikacije2011-06
URL dokumentahttps://doi.org/10.1007/s12253-010-9304-4
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 11:49:02